Free tool
Oncology stocks
We cover 106 companies grouped under the Oncology theme. The median market value in the group is $874.90M. Across the group, the median move over the past trading day is −0.52%. 72% of the 104 with a 200-day average trade above it. Price change over the past year runs from −23.0% to +309.9% across the middle 80 percent of the group, with a median of +61.2%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
106 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| HCM | HUTCHMED (China) Limited | $2.15B | Mid cap | −17.45% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| IMCR | Immunocore Holdings plc | $1.93B | Small cap | +13.69% |
| DMRA | Damora Therapeutics, Inc. | $1.89B | Small cap | +804.46% |
| VIR | Vir Biotechnology, Inc. | $1.87B | Small cap | +111.85% |
| INBX | Inhibrx Biosciences, Inc. | $1.81B | Small cap | +357.45% |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.77B | Small cap | +23.55% |
| BCAX | Bicara Therapeutics Inc. | $1.64B | Small cap | +105.74% |
| AAPG | Ascentage Pharma Group Internat | $1.58B | Small cap | −59.18% |
| AVBP | ArriVent BioPharma, Inc. | $1.54B | Small cap | +62.10% |
| REPL | Replimune Group, Inc. | $1.50B | Small cap | +187.16% |
| CGEM | Cullinan Therapeutics, Inc. | $1.48B | Small cap | +188.15% |
| AKTS | Aktis Oncology, Inc. | $1.47B | Small cap | +18.35% |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.44B | Small cap | +35.58% |
| IMTX | Immatics N.V. | $1.41B | Small cap | +74.63% |
| DRTS | Alpha Tau Medical Ltd. | $1.38B | Small cap | +343.92% |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.23B | Small cap | +207.92% |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.22B | Small cap | +167.82% |
| KURA | Kura Oncology, Inc. | $1.16B | Small cap | +66.16% |
| JANX | Janux Therapeutics, Inc. | $1.15B | Small cap | −19.10% |
| CADL | Candel Therapeutics, Inc. | $1.02B | Small cap | +124.70% |
| GERN | Geron Corporation | $995.83M | Small cap | +8.51% |
| OLMA | Olema Pharmaceuticals, Inc. | $949.35M | Small cap | +89.02% |
| ANL | Adlai Nortye Ltd. | $884.83M | Small cap | +791.12% |
| RIGL | Rigel Pharmaceuticals, Inc. | $864.97M | Small cap | +16.99% |
| NVCT | Nuvectis Pharma, Inc. | $816.10M | Small cap | +275.94% |
| AURA | Aura Biosciences, Inc. | $801.64M | Small cap | +20.03% |
| MNPR | Monopar Therapeutics Inc. | $763.31M | Small cap | +226.69% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $751.23M | Small cap | −0.43% |
| CTMX | CytomX Therapeutics, Inc. | $723.43M | Small cap | +60.39% |
| EIKN | Eikon Therapeutics, Inc. | $679.77M | Small cap | −20.13% |
| SGMT | Sagimet Biosciences Inc. | $675.04M | Small cap | +39.59% |
| CBIO | Crescent Biopharma, Inc. | $669.39M | Small cap | +26.46% |
| VSTM | Verastem, Inc. | $641.19M | Small cap | −20.45% |
| ARVN | Arvinas, Inc. | $609.40M | Small cap | +15.35% |
| DCTH | Delcath Systems, Inc. | $569.06M | Small cap | +49.91% |
| PRLD | Prelude Therapeutics Incorporated | $522.47M | Small cap | +412.50% |
| CCCC | C4 Therapeutics, Inc. | $521.63M | Small cap | +64.34% |
| TOI | Starling Oncology Inc | $512.91M | Small cap | +79.19% |
| RLMD | Relmada Therapeutics, Inc. | $485.35M | Small cap | +579.10% |
| PBYI | Puma Biotechnology, Inc. | $472.84M | Small cap | +79.61% |
| CMPX | Compass Therapeutics, Inc. | $437.61M | Small cap | −25.91% |
| FENC | Fennec Pharmaceuticals Inc. | $426.77M | Small cap | +34.62% |
| GALT | Galectin Therapeutics Inc. | $418.53M | Small cap | +4.27% |
| FHTX | Foghorn Therapeutics Inc. | $397.29M | Small cap | +23.66% |
| AGEN | Agenus Inc. | $371.33M | Small cap | +81.72% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $368.27M | Small cap | +113.74% |
| CATX | Perspective Therapeutics, Inc. | $360.72M | Small cap | −12.47% |
| STRO | Sutro Biopharma, Inc. | $355.50M | Small cap | +138.11% |
| IMRX | Immuneering Corporation | $333.19M | Small cap | −0.77% |
| BCYC | Bicycle Therapeutics plc | $304.03M | Small cap | −37.79% |
| PYXS | Pyxis Oncology, Inc. | $278.58M | Small cap | +145.59% |
| WHWK | Whitehawk Therapeutics, Inc. | $275.92M | Small cap | +167.40% |
| ALXO | ALX Oncology Holdings Inc. | $273.79M | Small cap | +65.00% |
| CGEN | Compugen Ltd. | $271.86M | Small cap | +93.20% |
| GLSI | Greenwich LifeSciences, Inc. | $267.58M | Small cap | +56.21% |
| ADAG | Adagene Inc. | $258.50M | Small cap | +75.80% |
| MGNX | MacroGenics, Inc. Common Stock | $257.35M | Small cap | +134.88% |
| IPHA | Innate Pharma S.A. | $253.56M | Small cap | +2.86% |
| TARA | Protara Therapeutics, Inc. | $231.06M | Small cap | +21.05% |
| CHRS | Coherus Oncology, Inc. | $224.03M | Small cap | +27.19% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $218.56M | Small cap | +7.93% |
| NBP | NovaBridge Biosciences | $216.26M | Small cap | −58.44% |
| CUE | Cue Biopharma, Inc. | $209.58M | Small cap | +16.42% |
| MOLN | Molecular Partners AG | $170.46M | Small cap | +18.67% |
| MENS | Jyong Biotech Ltd. | $170.30M | Small cap | −95.62% |
| KZIA | Kazia Therapeutics Limited | $166.83M | Small cap | +86.94% |
| OKUR | OnKure Therapeutics, Inc. | $155.52M | Small cap | +35.71% |
| ASRT | Assertio Holdings Inc | $151.86M | Small cap | +103.46% |
| INDP | Indaptus Therapeutics, Inc. | $145.90M | Small cap | −82.19% |
| HURA | TuHURA Biosciences, Inc. | $135.74M | Small cap | −26.55% |
| ADCT | ADC Therapeutics SA | $134.05M | Small cap | −67.39% |
| BDTX | Black Diamond Therapeutics, Inc. | $130.42M | Small cap | −20.91% |
| GNLX | Genelux Corporation | $123.52M | Small cap | −25.00% |
| ANIX | Anixa Biosciences, Inc. | $122.65M | Small cap | +22.20% |
| NTHI | NeOnc Technologies Holdings, Inc. | $122.16M | Small cap | −29.30% |
| ONCY | Oncolytics Biotech Inc. | $109.10M | Small cap | −19.28% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.